LVAD Market Report Overview
-
Request a Free Sample to learn more about this report
global lvad market size was USD 1016.8 million in the year 2022 and market is projected to touch 2208.41 Million by 2031, exhibiting a CAGR of 9% during the forecast period.
Left Ventricular Assist Device is referred to as LVAD. To assist the heart in pumping blood to the rest of the body, a mechanical pump is implanted into the left ventricle. These devices are typically utilized as a long-term therapy for individuals who are ineligible for heart transplantation or as a bridge to heart transplantation in severe heart failure patients. The aorta, the major artery that supplies the rest of the body with oxygenated blood, is pumped with blood that is drawn from the left ventricle by the gadgets. The device's driveline, which connects it to the pump, travels through the skin and is powered by a battery pack that is worn outside.
The left assist devices industry is expanding as a result of a number of causes, such as an ageing population, a rise in heart failure prevalence, improvements in the device technology, and a dearth of cardiac donors for transplants. For patients with advanced heart failure who cannot have a heart transplant or who are waiting for a donor heart, this instrument provides an additional therapy option. A greater spectrum of patients are now able to benefit from the devices as a feasible long-term therapy choice as the left assist device technology advances by making these devices smaller, more robust, and efficient.
COVID-19 Impact: Increased Demand Led to Short-term Supply Chain Issues
The COVID-19 epidemic has affected the devices business in a variety of ways. One significant outcome was a decline in the number of heart transplant operations conducted globally, which increased demand for LVADs as a bridge to transplant. Manufacturers had found it difficult to meet the increased demand, which had led to some short-term supply chain issues. As hospitals had to prioritize COVID-19 patients and restrict elective procedures, the pandemic also contributed to certain delays in gadget implantation surgery. A backlog of patients waiting for surgery has resulted from this, which may cause the demand for these devices to rise further in the months and years to come.
Latest Trends
"Development of Smaller Devices which Are Less Likely to Cause Various Complications"
The LVAD sector has recently seen a number of advancements targeted at enhancing patient outcomes and quality of life. The creation of smaller, more manageable devices that are less likely to cause complications such as bleeding and infection has been one of the most significant developments. The overall goals of these developments are to enhance patient outcomes, lessen the burden of device administration, and increase the viability of the assist gadgets as a long-term therapeutic choice for a larger spectrum of severe heart failure patients.
LVAD Market Segmentation
-
Request a Free Sample to learn more about this report
- By Type Analysis
According to type, the market can be segmented into BTT Therapy, BTD Therapy, Destination Therapy and BTR Therapy
- By Application Analysis
Based on application, the market can be divided into Hospitals and Ambulatory Surgical Centers
Driving Factors
"Ventricular Device Use Has Increased Due to Lack of Donor Hearts "
Worldwide, there is a severe lack of donor hearts, which has increased the usage of LVADs as a transitional therapy or as a long-term therapeutic option for patients who are ineligible for transplantation. Only roughly 39% of heart transplant candidates received a donor heart in 2020, according to the International Society for Heart and Lung Transplantation. As a result of this, there is a rising need for the assist devices, which can be a good choice for people with advanced heart failure.
"Patients' Quality of Life Is Improved Due to the Device's Benefits"
Patients with severe heart failure who are ineligible for cardiac transplantation have shown that LVADs increase survival. Long-term heart assistance with these gadgets enables patients to live longer and have better quality of life. Furthermore, by easing symptoms such as weariness and shortness of breath and enabling patients to resume regular activities, these devices can considerably enhance quality of life for those with severe heart failure. A second way that left ventricular devices can help patients' physical functioning and quality of life is by enhancing their participation in rehabilitation programmes.
Restraining Factors
"Individuals and Healthcare Systems may be Burdened Significantly by the High Costs Associated with these Devices"
The high price of the left ventricular assist therapy is one of the main constraints limiting the LVAD market growth. In addition to the complicated and pricey processes involved in their implantation and care, the devices themselves can be very expensive. In lower-income nations where healthcare systems would not be able to afford the expense of these devices, this can render the assist devices therapy inaccessible to many people who could benefit from it. The long-term costs of the therapy can also be high, including the price of continuing device maintenance and monitoring. The broad use of this type of therapy may be constrained by this, which can be a considerable burden for individuals and healthcare systems.
LVAD Market Regional Insights
-
Request a Free Sample to learn more about this report
"Established Healthcare Infrastructure is Promoting the Regional Devices Market Expansion "
The healthcare system in North America is well-established, with many skilled medical personnel and specialized hospitals that can handle difficult procedures such as the implantation and treatment of the assist devices. With numerous commercial insurance policies and government programmes covering the cost of the device installation and administration, North America has a favorable reimbursement environment for the left assist device therapy. For patients in the area, this increases access to and affordability of ventricular therapy. There are many well-established centers in North America, which has helped the technology's advancement and uptake. Overall, these elements have helped North America dominate the LVAD market share and are probably going to do so in the years to come.
Key Industry Players
"Key Players Focus on Geographical Expansions and Strategic Alliances to Gain a Competitive Advantage"
By entering new markets and forming alliances with distributors and healthcare providers in various areas, the manufacturers are attempting to increase the geographic scope of their business. This entails stepping into developing nations such as Latin America and Asia Pacific, where the prevalence of heart failure is sharply rising. To further develop and improve their products, the manufacturers are forming strategic alliances and working together with healthcare organizations, research centers, and other stakeholders. Through these partnerships, producers may be able to gain access to cutting-edge equipment, knowledge, and resources that can spur development and innovation.
List of Market Players Profiled
- Abiomed (U.S.)
- Berlin Heart (Germany)
- HeartWare International (U.S.)
- Jarvik Heart (U.S.)
- Abbott (U.S.)
- Cardiac Assist (U.S.)
- Evaheart (U.S.)
- ReliantHeart (U.S.)
- Sun Medical Technology Research (Japan)
- Sunshine Heart (U.S.)
Report Coverage
This report covers the LVAD market. The CAGR expected to be in during the forecast period, and also the USD value in 2022 and what it is expected to be in 2031. The effect COVID-19 had on the market in the beginning of the pandemic. The latest trends taking place in this industry. The factors that are driving this market as well as the factors that are restraining the growth of industry. The segmentation of this market based on type and applications. The region leading in the industry and why they will continue to do so during the forecast period. Further, the key market players, what all is being done by them to stay ahead of their competition as well as retain their market positions. All these details are covered in the report.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 1016.8 Million in 2022 |
Market Size Value By |
US$ 2208.41 Million by 2031 |
Growth Rate |
CAGR of 9% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the global LVAD market expected to touch by 2031?
The global LVAD market is expected to touch USD 2208.41 Million by 2031.
-
What CAGR is the LVAD market expected to exhibit during 2024-2031?
The LVAD market is expected to exhibit a CAGR of 9.0% over 2024-2031.
-
Which are the driving factors of the LVAD market?
Ventricular device use has increased due to lack of donor hearts and patients quality of life Is improved due to the devices benefits are the driving factors of the LVAD market.
-
Which are the top companies operating in the LVAD market?
Abiomed, Berlin Heart, HeartWare International, Jarvik Heart and Abbott are the top companies operating in the LVAD market.